Restacorin, a new antiarrhythmic drug: a review of its electrophysiologic and hemodynamic properties.
Restacorin is a recently developed effective antiarrhythmic agent with primarily class Ic properties. The present paper reviews the electrophysiologic and hemodynamic effects of this compound. The major electrophysiologic effects are a depression of Vmax and an increase in AH, HV and QRS duration. The administration of restacorin does not induce significant side effects. In subjects with a normal left ventricular function, restacorin does not show negative inotropic effects. However, in patients with a decreased left ventricular function, restocorin produces a moderate negative inotropic effect.
Tuininga
Y S
YS
Department of Cardilogy, Thoraxcenter, University Hospital Groningen, The Netherlands.
Crinjns
H J
HJ
Kozma
C
C
Rabloczky
G
G
Jonkman
J H
JH
Lie
K I
KI
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D004594:Electrophysiology; D006146:Guanidines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans
D000889:Anti-Arrhythmia Agents; D006146:Guanidines; C059816:restacorin